Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Disease description
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Disease description

39 evidence topics · 35 sources

Definition and etiology2 evidence topics · 2 sources
Epidemiology4 evidence topics · 5 sources
Natural history, survival, and mortality3 evidence topics · 3 sources
Pathophysiology2 evidence topics · 2 sources
Diagnosis2 evidence topics · 3 sources
Clinical presentation - signs and symptoms1 evidence topic · 2 sources
Long-term morbidity2 evidence topics · 2 sources
Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies23 evidence topics · 20 sources